MYOK News

IPO investors are beginning to see pre-IPO valuations. A biotech and a semiconductor company went public this past week after slashing their proposed valuations. While health care has remained strong all year, more ...read more

MyoKardia, a clinical-stage biotech developing therapies for heritable cardiomyopathies, raised $54 million by offering 5.4 million shares at $10.00, below the range of $15 to $17. MyoKardia plans to list on the Nasdaq under the symbol MYOK. Credit Suisse and Cowen & Company acted as lead managers on the deal....read more

Just one new company is scheduled to price this week. Three small initial public offerings have delayed IPOs for two weeks or more, and again join the IPO calendar. In the past week, the VIX Volatility Index fell to a 2-month low and the S&P 500 reached a 2-month high - roughly where each was...read more

MyoKardia, a clinical-stage biotech developing therapies for heritable cardiomyopathies, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $75 million by offering 4.7 million shares at a price range of $15 to $17. At the midpoint of the proposed range, MyoKardia would command a fully diluted market value of $425 million. ...read more